VALBIOTIS

Valbiotis has adopted an innovative approach, aiming to revolutionize healthcare by developing a new class of health nutrition products designed to reduce the risk of major complex metabolic and cardiovascular diseases, based on a multi-target approach enabled by the use of plant-based ingredients.

Valbiotis’ mission is to reduce the impact of these diseases on millions of patients diagnosed at an early stage in the world, in order to prevent them from developing such pathologies.

The active substances of the pipeline, which are specific combinations of plant molecules called “TOTUM”, act simultaneously upon metabolic parameters to correct dysfunctions and halt their progression at the earliest stage of disease.

These four innovative active substances are intended for people at risk of developing type 2 diabetes, cardiovascular diseases, NASH (non-alcoholic steatohepatitis). Clinical development plans aim at obtaining specific health claim authorizations for each product from regulatory authorities such as the FDA (Food and Drug Administration in the United States), the EFSA (European Food Safety Authority in Europe) and other country-specific authorities.

Internationally, its products are intended to be the subject of licensing and/or distribution agreements with global or regional health and nutrition players. In France, except for TOTUM•63, Valbiotis will be responsible for marketing its own products.

The products are intended to be licensed to players in the health sector. In February 2020, the Company signed a first global strategic partnership ith Nestlé Health Science for the development and worldwide marketing of TOTUM•63, in the prediabetes market.

Created at the beginning of 2014 in La Rochelle, the Company has forged numerous partnerships with leading academic centers. The Company has 51 employees and has established three sites in France, including 2 R&D centers – Périgny, La Rochelle (17) and Riom (63) – and has a subsidiary in Quebec City (Canada).